Homepage
Author:
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
Posted Date:
May 12, 2026
Keenova Reports First Quarter 2026 Financial Results
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 12, 2026
Keenova Launches New Consumer Campaign for Dupuytren’s Contracture: Don’t Be a Viking
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 8, 2026
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 8, 2026
Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 7, 2026
Keenova Announces Unaudited Fourth Quarter 2025 Financial Results
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 4, 2026
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 4, 2026
Keenova Therapeutics to Report Fourth-Quarter 2025 Financial Results on March 31, 2026
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
May 2, 2026
Keenova Publishes XIAFLEX® (collagenase clostridium histolyticum) Analysis in Journal of Hand Surgery Global Online
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
April 30, 2026
Keenova Unveils Clinical Data from Phase 2 Plantar Fibromatosis Study at the ACFAS Annual Meeting
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
February 24, 2026
Keenova Announces New Manuscript on Plantar Fibromatosis Treatment Patterns in Peer-Reviewed Journal of Foot and Ankle Surgery
ST Shared Services LLC dba Mallinckrodt Pharmaceuticals
February 16, 2026
